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Background: Continuous infusion of levodopa-carbidopa intestinal gel (LCIG) can effectively manage
motor and non-motor complications in advanced Parkinson’s disease (PD). Healthcare costs, quality of
life (QoL), effectiveness, and tolerability were assessed in routine care treatment with LCIG.
Methods: The seventy-seven patients enrolled in this prospective, open-label, 3-year study in routine
medical care were LCIG-naïve (N ¼ 37), or had previous LCIG treatment for <2 (N ¼ 22), or 2 (N ¼ 18)
years. Healthcare costs were collected monthly. PD symptoms and QoL were assessed with the Uniﬁed
Parkinson’s Disease Rating Scale (UPDRS), 39-item Parkinson’s Disease Questionnaire (PDQ-39), and
EuroQoL 5-Dimension Visual Analog Scale (EQ-5D VAS); LCIG dose, safety, and tolerability were
monitored.
Results: Mean monthly costs per patient (V8226 ± 5952) were similar across cohorts, remained steady
during 3-year follow-up, and increased with PD severity and QoL impairment. In LCIG-naïve patients,
signiﬁcant improvements compared to baseline were observed on the UPDRS total score and PDQ-39
summary index score through 18 months (n ¼ 24; UPDRS, p ¼ 0.033; PDQ-39, p ¼ 0.049). Symptom
control was maintained during 3-year follow-up in LCIG-experienced cohorts. Small changes in mean
daily LCIG dose were observed. Adverse events were common and generally related to the device,
procedure, levodopa, or laboratory evaluations.
Conclusions: Costs in LCIG-treated patients were stable over 3 years. LCIG treatment led to signiﬁcant
improvements in motor function and QoL over 18 months in LCIG-naïve patients and no worsening was
observed in LCIG-experienced patients over 3 years despite natural PD progression over time. The long-
term safety was consistent with the established LCIG proﬁle.
© 2016 AbbVie Inc. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Karolinska University Hospi-
Pålhagen).
td. This is an open access article un1. Introduction
After long-term treatment with oral levodopa, Parkinson’s dis-
ease (PD) patients develop motor ﬂuctuations and involuntaryder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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daily activities and social interactions, and substantially impact
quality of life (QoL) [1]. There is evidence that dyskinesia results
from short-duration levodopa response and sensitization of post-
synaptic receptors by pulsatile oral dopaminergic stimulation [2].
Clinical study results show that continuous dopaminergic delivery
provides more stable levodopa plasma levels compared to oral
treatment and control motor and non-motor symptoms in patients
with advanced PD [3].
Levodopa-carbidopa intestinal gel (LCIG) is a stable suspension
of levodopa and carbidopa, and suitable for continuous delivery via
percutaneous endoscopic gastrostomy (PEG) tube with a duodenal
extension. LCIG infusion reduced motor and non-motor complica-
tions in a randomized, placebo-controlled trial [4], open-label tri-
als, and retrospective investigations extending over follow-up
periods of one [5,6] to three years [7e9]. To date, there are few
long-term prospective studies assessing healthcare costs associated
with LCIG use; one report indicated that compared to standard oral
medication, gains in quality-adjusted life years for LCIG were
inﬂuenced by treatment duration and baseline disease character-
istics [10]. A recent study of 10 patients prospectively followed for
12 months showed improvement in motor function and safety, but
at an increased cost [11].
The objective of this study was to assess healthcare costs over 3
years, including drug, direct medical, direct non-medical, and in-
direct costs; to evaluate the impact of LCIG treatment duration and
disease severity on healthcare costs; and tomonitor long-term LCIG
effectiveness and safety in routine medical care. Twelve-month
interim results in the LCIG-naïve cohort were previously pub-
lished [12].
2. Methods
2.1. Study design
This prospective, open-label, long-term study (EudraCT #2005-
002654-21) was conducted in routine carewith 3-year follow-up at
10 sites between March 2006 and April 2011. The study was
approved by the Regional Committee for Medical and Health
Research Ethics at the University Hospital in Trondheim, Norway. In
Sweden, the ethical review board considered this investigation as
patient follow-up, and approval was not required. Patient signed
informed consent was obtained before any study-related
procedures.
2.2. Patients
Patients on LCIG for 12 weeks prior to the study or naïve to
LCIG were eligible. For LCIG-naïve patients, investigators had to
consider a change from conventional PD treatment. Criteria for
treatment according to the Summary of Products Characteristics
(SmPC) for Duodopa® had to be fulﬁlled. Patients suffering from
diseases that, in the opinion of the investigator, might interfere
with the study objectives or those who the investigator determined
to be unable to comply with study requirements were excluded.
Patients were allocated to one of the three cohorts: LCIG-naïve,
LCIG treatment <2 years (LCIG<2Y) or 2 years (LCIG2Y).
2.3. Study assessments
LCIG-naïve patients were assessed while on conventional PD
treatment before the initial LCIG infusion: month (M) 3 repre-
sents baseline before the initial LCIG infusion and M0 indicates the
start of LCIG treatment. Baseline assessments for LCIG<2Y and
LCIG2Y cohorts were at study inclusion (M0). Follow-up visitswere conducted every 3 months up to M12 and every 6 months
thereafter through M36.
Direct medical, direct non-medical, indirect, and drug-related
costs were collected monthly through phone interviews by study
nurses (Supplementary Table 1). The consumption of healthcare
resources was costed out with national product- or service-speciﬁc
unit costs (Supplementary Table 2). Costs obtained in Swedish
Kronor (2010 index) were converted to Euro using the median
exchange rate of 2010.
Health-related QoL was measured utilizing the 39-item Par-
kinson’s Disease Questionnaire (PDQ-39) and EuroQoL 5-
Dimensions Visual Analog Scale (EQ-5D VAS). PD symptoms were
measured by the Uniﬁed Parkinson’s Disease Rating Scale (UPDRS),
the PD stage and best “on” time were assessed with the Hoehn and
Yahr (HY) scale, and activities of daily living were measured by the
Schwab and England Activity of Daily Living (ADL) Scale. Cognition
and mood/depression were monitored using the Mini-Mental State
Examination (MMSE) and Montgomery-Åsberg Depression Rating
Scale (MADRS). Mean daily LCIG doses (morning dose, continuous
maintenance dose, and extra bolus) were recorded by volume of gel
(mL) and converted to mg levodopa.
To monitor safety of LCIG treatment, vital signs, clinical labo-
ratory assessments, ECG, and treatment-emerged adverse events
(AEs) were recorded. AE classiﬁcation was determined by the
investigator. AEs were deﬁned as those occurring on the ﬁrst day of
LCIG treatment (LCIG-naïve cohort) or inclusion to study (LCIG-
experienced cohorts) through 7 days after the last LCIG infusion or
end of study participation.
2.4. Statistical analyses
To evaluate healthcare costs, it was estimated that 75 patients
should be recruited. One protocol-deﬁned interim analysis was
performed presenting 12-month outcomes of the LCIG-naïve
cohort [12]. No adjustment for multiplicity was applied. Clinical
data were analyzed using descriptive statistics. AWilcoxon signed-
rank test was used for statistics of efﬁcacy and QoL data analyzing
change from baseline (M-3 for LCIG-naïve cohort; M0 for LCIG-
experienced cohorts).
3. Results
3.1. Patients
Seventy-seven patients enrolled in the study. All patients except
one were treated with LCIG and allocated to LCIG-naïve (N ¼ 36),
LCIG<2Y (N¼ 22), or LCIG2Y (N¼ 18). In the LCIG-naïve cohort, 15
patients (41.7%) terminated the study prematurely: due to AEs
(n ¼ 7), lack of efﬁcacy (n ¼ 5), withdrawal of consent (n ¼ 2), and
protocol violation (n ¼ 1). Six patients (27.3%) in the LCIG<2Yand 6
patients (33.3%) in the LCIG2Y cohort prematurely terminated the
study due to AEs (n ¼ 5, n ¼ 2), protocol violation (n ¼ 1, n ¼ 2), or
withdrawal of consent (n ¼ 0, n ¼ 2) (Supplementary Fig. 1).
Disease characteristics reported at M0 (3 months after LCIG
initiation for LCIG-naïve patients) are presented in Table 1. The
mean (SD) duration of prior LCIG infusion at M0 in the LCIG<2Yand
LCIG2Y was 1.2 (0.7) and 3.5 (1.3) years, respectively. Age, PD
symptom scale scores, and QoL measures were lower on average in
the LCIG-naïve cohort and higher in the LCIG2Y cohort, while
similar cognitive and mental scores were seen across cohorts
(Table 1).
3.2. Healthcare costs
The mean total monthly costs per patient were similar in all
Table 1
Demographics and disease characteristics at month 0.a
Mean (SD) LCIG-naïve N ¼ 27 LCIG <2 years N ¼ 22 LCIG 2 years N ¼ 18
Demographics
Age, years 64.6 (6.4) 65.4 (5.2) 66.6 (8.7)
Age at Parkinson’s disease diagnosis, years 53.9 (5.1) 51.3 (6.2) 49.1 (10.9)
Age at initiation of levodopa treatment, years 54.1 (5.1) 51.2 (6.2) 49.1 (10.7)
Duration of LCIG treatment at Month 0, years 0.4 (0.1) 1.2 (0.7) 3.5 (1.3)
Uniﬁed Parkinson’s disease rating scale
Total Score 43.1 (16.7) 46.2 (17.3) 47.8 (16.4)
Part I: Mentation, Behavior and mood 2.4 (1.8) 2.0 (1.8) 2.7 (1.8)
Part II: Activities of daily living 12.3 (5.1) 13.7 (6.3) 15.4 (5.9)
Part III: Motor examination 22.0 (9.7) 23.4 (11.1) 22.4 (9.8)
Part IV: Complications of therapy 6.5 (2.7) 7.1 (3.4) 7.2 (3.0)
Hoehn and Yahr
Best “on” stage during last month 2.0 (0.9) 2.5 (0.7) 2.5 (0.7)
Worst stage during last month 3.6 (1.1) 3.7 (0.9) 4.0 (0.6)
EuroQol-5 dimensions
Societal preferences (Descriptive Score) 0.67 (0.27) 0.68 (0.27) 0.62 (0.24)
Individual preferences (Visual Analog Scale) 0.68 (0.18) 0.65 (0.18) 0.58 (0.23)
39-item Parkinson’s disease questionnaire summary index 27.1 (11.8) 30.3 (10.7) 36.6 (15.4)
Schwab and England activities of daily living scale 80.4 (13.2) 75.5 (14.4) 74.4 (11.5)
Mini-mental status examination 27.8 (2.4) 28.0 (2.2) 28.2 (1.4)
Montgomery-Åsberg depression rating scale 9.0 (5.3) 7.8 (5.2) 8.8 (5.8)
LCIG, levodopa-carbidopa intestinal gel.
a Month 0 was the ﬁrst follow up  3 months after LCIG initiation for LCIG-naïve cohort and the study enrollment for LCIG<2Y and LCIG2Y cohorts.
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similar to M0 throughout the 3-year follow-up. The increase be-
tween M-3 and M0 on drug costs was due to the initiation of LCIG
treatment in the LCIG-naïve cohort (Fig. 1b). The monthly costs per
patient increased in relation to severity of PD symptoms and QoL
impairment (Fig. 1c, d).
3.3. Effectiveness
In the LCIG-naïve cohort, the mean UPDRS total score decreased
from baseline to ﬁrst follow-up and was maintained through M18
(p ¼ 0.033) (Fig. 2a). The mean (SD) UPDRS Part IV score decreased
from 9.4 (2.6) at baseline to 6.5 (2.7) at M0 (p < 0.001) and 6.4 (3.0)
at M36 (p < 0.001). The mean UPDRS Part II score decreased from
15.5 (5.7) at baseline to 12.3 (5.1) at M0 (p < 0.005) and 12.9 (7.7) at
M24 (p ¼ 0.024). The mean UPDRS Part III score decreased from
24.4 (11.0) at baseline to 22.0 (9.7) at M0 (p < 0.005). There were no
signiﬁcant changes in the mean UPDRS Part I score at any time
point compared with baseline. The mean PDQ-39 total score
decreased fromM0 (p < 0.001) through M9 and at M18 (p ¼ 0.049)
(Fig. 2b), and the mean EQ-5D VAS improved from M0 (p < 0.001)
through M36 (p ¼ 0.043) (Fig. 2c).
In LCIG-experienced cohorts, EQ-5D VAS scores numerically
improved over the course of the study (Fig. 2c), while the PDQ-39
Summary Index initially decreased (improvement) in the ﬁrst
months and then numerically increased (deteriorated) until the last
visit (Fig. 2b). The mean HY, ADL, MMSE, and MADRS scores
remained unchanged in all cohorts throughout the 3-year follow-
up.
3.4. Drug exposure and safety
The mean daily levodopa dose was generally stable from M0
through M36, with only a small numerical increase in daily levo-
dopa dose observed in LCIG-naïve patients over 3 year follow-up
(Table 2). In the LCIG-naive cohort, 80.6% of patients experienced
AEs, and all patients in the LCIG<2Y and LCIG2Y cohorts reported
at least one AE (Table 2). Many AEs were related to the device and
associated procedures: device removals/changes, tube dislocations
or occlusions, stoma site infections, excessive granulation tissue, orinfections. The other clusters of AEs consisted of events related to
PD or levodopa such as gastrointestinal disorders or psychiatric
disorders, and were reported by comparable proportions of pa-
tients in all cohorts. Two events of polyneuropathy were reported.
The AEs most commonly leading to study termination were delu-
sion (n ¼ 2 patients), dementia (n ¼ 2), device related infection
(n ¼ 2), and medical device complication (n ¼ 2); the speciﬁc AEs
leading to discontinuation for 2 patients were not reported.
Mean laboratory parameters were generally similar in all co-
horts and typically remained stable during 3-year follow-up. For
LCIG-naïve, LCIG<2Y and LCIG2Y respectively, mean (SD) vitamin
B12 levels increased from M0, 499.1 (529.7), 401.5 (214.4), and
472.4 (277.5) pmol/L by 200.7 (752.2), 226.1 (367.4), and 250.0
(592.2) pmol/L. Mean (SD) folic acid levels increased fromM0,120.2
(218.8), 102.3 (150.2), and 86.3 (131.8) nmol/L by 161.2 (435.9),141.0
(435.9), and 42.1 (181.8) nmol/L. Mean homocysteine levels
decreased slightly from M0, 22.7 (10.4), 19.6 (6.2), and 21.4 (9.7)
mmol/L by 2.9 (13.34), 0.2 (6.1) and 1.5 (8.3) mmol/L at the ﬁnal
visit.
Four deaths were reported in this study: two in the LCIG-naïve
and two in the LCIG<2Y cohorts. The relationship to study drug was
classiﬁed by the local study investigator to be unrelated (n ¼ 2),
unlikely related (n ¼ 1; drug toxicity related to medications for
depression, anxiety, and pain: codeine, paracetamol, mirtazapine,
and zopiclone) and possibly related (n ¼ 1; cardiac arrest).4. Discussion
This study represents the largest prospective, long-term study
evaluating healthcare costs and clinical effectiveness including
patient-reported QoL in advanced PD patients treated with LCIG for
various durations (naïve, <2 and  2 years). The long study dura-
tion allowed evaluation of outcomes throughout 3 years of follow-
up, extending up to a maximum of 6.5 years LCIG exposure in some
patients. LCIG-naïve patients included in this study represent a
cohort of advanced PD patients similar to routine care populations
described in other open-label [6,9] and randomized, controlled [4]
trials.
Interestingly, the average monthly costs per patient were
generally similar across cohorts suggesting stabilization of PD
Fig. 1. Mean monthly healthcare costs per patient. a by LCIG experience; (b) over time (all cohorts combined); (c) by “off” time at baseline; and, (d) by PDQ-39 score intervals at
baseline. Costs were collected in Swedish Kronor (Index 2010) for each patient on a monthly basis and converted to Euro using the median exchange rate from 2010: n ¼ 37 (LCIG-
naïve), n ¼ 22 (LCIG<2 years), n ¼ 18 (LCIG2 years).
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treatment. This might be unexpected since baseline disease char-
acteristics showed a gradual higher age, advanced disease stage,
increased severity of symptoms, and impaired QoL across cohorts,
likely reﬂecting the different disease states at start of the 3-year
follow-up, and suggesting sustained LCIG beneﬁts across a range
of patient characteristics. The only difference over time was an
increase in drug-related costs in the LCIG-naïve cohort between
baseline (M-3) and ﬁrst follow-up visit (M0), due to initiation of
LCIG treatment; costs in the LCIG-naïve cohort then remained un-
changed over the subsequent 3 years. Notably, costs were higher for
patients with more severe PD symptoms according to “off” time, or
withmore affected QoL, so healthcare costs may be better managed
in patients with less severe advanced PD. Similarly, a comparison
between patients treated with LCIG and matched patients on
conventional treatment showed evidence for cost-effectiveness ofLCIG in advanced PD patients [10].
Efﬁcacy results in the LCIG-naïve cohort with LCIG initiation
showed marked improvements relative to baseline. In the two
LCIG-experienced cohorts, all efﬁcacy assessments were stable,
reﬂecting preservation of PD status, motor performance, and QoL
over 3 years. Comparable improvements in UPDRS scores were
reported in other, shorter studies, which have also demonstrated
that the largest improvements in PD motor symptoms and QoL are
typically observed in the immediate months following initiation of
LCIG treatment [3,4,13,14,21]. To our knowledge, no other study
reported signiﬁcant improvements of motor complications that
were maintained over a 3-year follow-up with QoL beneﬁts, and
this is the ﬁrst report of LCIG efﬁcacy up to 6.5 years. Similar ben-
eﬁts in QoL (PDQ-39 and EQ-5D) were shown recently in open-
label, routine-care studies [6,15] and a randomized, controlled
trial [4].
Fig. 2. Clinical efﬁcacy over time by LCIG experience. a Uniﬁed Parkinson’s Disease
Rating Scale (UPDRS) total score; (b) Parkinson’s Disease Questionnaire (PDQ-39) total
score; and, (c) EuroQol 5-Dimensions visual analog scale (EQ-5D VAS). Asterisks (*)
represent signiﬁcant changes (p  0.05) based on a Wilcoxon signed-rank test
compared to baseline for LCIG-naïve patients. M-3: n ¼ 36 (LCIG-naïve baseline); for
LCIG-naïve, LCIG<2 years and LCIG2 years cohorts, M0: n ¼ 27, 22, and 18; M12:
n ¼ 25, 20, and 17; M24: n ¼ 23, 18, and 15; M36: n ¼ 21, 16, and 12.
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nance beneﬁts observed during ongoing LCIG treatment were
achieved in all three cohorts without signiﬁcant changes of average
daily LCIG dose over 3 years. Other studies conducted in routine
care also reported stable LCIG doses over time suggesting that
tolerance does not develop with long-term LCIG treatment [8,9].
Nearly all patients experienced at least one AE, mostly
commonly an event related to the device or associated procedures.
The higher rate of premature terminations observed in LCIG-naïve
patients relative to the LCIG-experienced patients may represent a
higher potential for AEs during LCIG initiation. Reported incidences
of device complications were similar in an open-label study [14]
and higher in a randomized, controlled trial [4]. Rates of AEs clas-
siﬁed as “psychiatric disorders” and “gastrointestinal disorders” are
consistent with the overall proﬁle in advanced PD patients [14e16]
and have also been described for oral levodopa-carbidopa [13]. The
pattern and frequency of AEs were consistent with the known
safety proﬁle based on previous clinical studies [6e9].
Long-term levodopa exposure has been associated with
decreased vitamin B12 and increased homocysteine levels [17].
Counterintuitively, in this study, mean values of vitamin B12 and
folic acid increased and mean homocysteine levels decreased.
Despite this population trend, some AEs of vitamin B12 deﬁciency
or hyper-homocysteinaemia were reported; however, these were
not paralleled by clinical abnormalities. Two cases of poly-
neuropathy were reported, which were mild and considered un-
related by the study investigator. Polyneuropathy has been
discussed as a possible complication of LCIG infusion and is listed as
potential adverse drug reaction in the SmPC of LCIG, however, the
etiology remains unclear [18e20]. Prophylactic vitamin B12 sup-
plementation during LCIG treatment has been proposed [17,20].
Many patients used concomitant supplements in this study, which
may have induced the observed laboratory trends and confounded
the inﬂuence of LCIG. Limitations of data assessments in this study
conducted in routine care (different laboratories and reference
ranges in participating hospitals, variations in the initiation of
vitamin supplementation) prevent a detailed investigation of the
vitamin-related ﬁndings.
Although this study bears some design-related limitations such
as the open-label nature and lack of a control arm, the standardized
format of healthcare cost collection and utilization of validated QoL
assessments during routine medical care support the robustness of
data. Therefore, we consider that outcomes represent “real world”
clinical practice. In addition, ﬁndings are consistent with results in
other open-label studies and a randomized, controlled trial [4e9].
In conclusion, this prospective, long-term study in routine
medical care demonstrated signiﬁcantly improved PD symptoms
and QoL through 18M and stable motor function over 3 year follow-
up in LCIG-naïve advanced PD patients, despite natural progression
of PD over time. Additionally, the data demonstrate stable health-
care costs over 3 years and a signiﬁcant inﬂuence of disease severity
and QoL on healthcare costs. The consistency in healthcare costs
across cohorts reﬂects the signiﬁcant effectiveness after LCIG
initiation in naïve patients and sustained stabilization of disease
symptoms and QoL throughout LCIG treatment. Combined, the
improvement and maintenance in patients treated with LCIG, and
the evidence of a correlation between healthcare costs and disease
severity are suggestive that LCIG treatment may contribute to sta-
bilizing long-term costs. The economic and clinical outcomes
combined with the relative safety and tolerability of LCIG indicates
that LCIG treatment has an appropriate beneﬁt-risk proﬁle to
consider for long-term treatment of PD.
Table 2
Summary of adverse events and levodopa exposure.
LCIG-Naïve N ¼ 36 LCIG <2 Years N ¼ 22 LCIG 2 Years N ¼ 18
Mean (SD) total daily levodopa dose M0 1654 (548) 1366 (488) 1514 (886)
M12 1784 (724) 1376 (496) 1650 (884)
M24 1898 (794) 1410 (530) 1448 (502)
M36 1848 (734) 1494 (512) 1572 (596)
Any adverse event 29 (80.6%) 22 (100.0%) 18 (100.0%)
Adverse events occurring in >10% of any cohort
System organ class Preferred term
Blood and lymphatic system disorders Anaemia 7 (19.4%) 5 (22.7%) 3 (16.7%)
Gastrointestinal disorders Constipation 8 (22.2%) 3 (13.6%) 5 (27.8%)
Oesophagitis e 1 (4.5%) 3 (16.7%)
Infections and infestations Bronchitis e e 2 (11.1%)
Device related infection 7 (19.4%) 6 (27.3%) 5 (27.8%)
Pneumonia 4 (11.1%) 2 (9.1%) 2 (11.1%)
Urinary tract infection 3 (8.3%) 4 (18.2%) 4 (22.2%)
Injury, poisoning and procedural complications Device dislocation 10 (27.8%) 9 (40.9%) 6 (33.3%)
Device occlusion 5 (13.9%) 1 (4.5%) 2 (11.1%)
Fall 2 (5.6%) 5 (22.7%) 4 (22.2%)
Medical device complication 1 (2.8%) e 2 (11.1%)
Investigations Blood homocysteine increased 2 (5.6%) 4 (18.2%) 6 (33.3%)
Metabolism and nutrition disorders Dehydration 1 (2.8%) e 2 (11.1%)
Hyperhomocysteinaemia 4 (11.1%) 1 (4.5%) e
Vitamin b12 deﬁciency 1 (2.8%) 3 (13.6%) 1 (5.6%)
Musculoskeletal and connective tissue disorders Back pain 5 (13.9%) 4 (18.2%) 3 (16.7%)
Nervous system disorders Dizziness e e 2 (11.1%)
Dyskinesia 2 (5.6%) 1 (4.5%) 2 (11.1%)
Psychiatric disorders Depression 7 (19.4%) 4 (18.2%) 2 (11.1%)
Hallucination 11 (30.6%) 3 (13.6%) 3 (16.7%)
Insomnia 6 (16.7%) 3 (13.6%) 1 (5.6%)
Renal and urinary disorders Micturition urgency e 6 (27.3%) 2 (11.1%)
Urinary incontinence 1 (2.8%) 3 (13.6%) e
Skin and subcutaneous tissue disorders Excessive granulation tissue 6 (16.7%) 7 (31.8%) 2 (11.1%)
Surgical and medical procedures Medical device change 15 (41.7%) 14 (63.6%) 4 (22.2%)
Medical device removal 1 (2.8%) 3 (13.6%) e
LCIG, levodopa-carbidopa intestinal gel; M, month.
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